Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04285567
Title A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation (CRISTALLO)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Hoffmann-La Roche
Indications

chronic lymphocytic leukemia

Therapies

Obinutuzumab + Venetoclax

Bendamustine + Rituximab

Cyclophosphamide + Fludarabine + Rituximab

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP

Additional content available in CKB BOOST